YH-53,98.78%

产品编号:Bellancom-139311| CAS NO:1471484-62-4| 分子式:C30H33N5O5S| 分子量:575.68

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-139311
5000.00 杭州 北京(现货)
Bellancom-139311
8500.00 杭州 北京(现货)
Bellancom-139311
16500.00 杭州 北京(现货)
Bellancom-139311
26000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

YH-53

产品介绍 YH-53 是一种有效的 3CLpro 抑制剂,对 SARS-CoV-1 3CLpro 和 SARS-CoV-2 3CLproKi 值分别为 6.3 nM、34.7 nM。YH-53 强烈阻止 SARS-CoV-2 复制。YH-53 是一种具有独特苯并噻唑基酮的拟肽化合物。YH-53 具有用于 COVID-19 研究的潜力。
生物活性

YH-53 is a potent 3CLpro inhibitor with Ki values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CLpro and SARS-CoV-2 3CLpro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research.

体外研究

YH-53 (1-25 μM; for 24 h) efficiently reduces copies of total RNA with increased concentrations in VeroE6/TMPRSS2 cells.
YH-53 (1, 5, 10, 15, 20, 25 μM; for 48 h) with 10 μM completely blocks the viral proliferation against SARS-CoV-2 were examined by a cytopathic effect (CPE) assay in Vero cells.
YH-53 (10, 100 μM; for 24 h) has no cytotoxicity with a CC50 value of >100 μM in vero cells.
YH-53 (10 μM) moderately inhibits CYP1A2, CYP2D6, and CYP2C8 (26.6%, 38.0%, 66.4%, respectively). YH-53 has no inhibition on CYP2C9 and CYP3A4.
YH-53 inhibits SARS-CoV 3CLpro with an IC50 of 0.74 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line: VeroE6/TMPRSS2 cells
Concentration: 1, 5, 10, 15, 20, 25 μM
Incubation Time: 24 hours
Result: Efficiently reduced copies of total RNA.
体内研究
(In Vivo)

YH-53 (0.1 mg/kg; iv) has a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg in rats.
YH-53 (0.5 mg/kg; oral) has a T1/2 of 9.64 hours, an AUC0–∞ of 3.49 ng•h/mL, a Cmax of 1.08 ng/mL in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats
Dosage: 0.1 mg/kg (Pharmacokinetic Analysis)
Administration: IV
Result: Had a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg.
体内研究

YH-53 (0.1 mg/kg; iv) has a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg in rats.
YH-53 (0.5 mg/kg; oral) has a T1/2 of 9.64 hours, an AUC0–∞ of 3.49 ng•h/mL, a Cmax of 1.08 ng/mL in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats
Dosage: 0.1 mg/kg (Pharmacokinetic Analysis)
Administration: IV
Result: Had a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg.
体内研究

YH-53 (0.1 mg/kg; iv) has a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg in rats.
YH-53 (0.5 mg/kg; oral) has a T1/2 of 9.64 hours, an AUC0–∞ of 3.49 ng•h/mL, a Cmax of 1.08 ng/mL in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats
Dosage: 0.1 mg/kg (Pharmacokinetic Analysis)
Administration: IV
Result: Had a T1/2 of 2.97 hours, an AUC0–∞ of 19.7 ng•h/mL, a Vd of 3.51 L/kg.
性状Solid
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (86.85 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7371 mL 8.6854 mL 17.3708 mL
5 mM 0.3474 mL 1.7371 mL 3.4742 mL
10 mM 0.1737 mL 0.8685 mL 1.7371 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (3.61 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (3.61 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服